New technology has potential to save lives, save costs, produce more accurate data and perform clinical trials faster
SALT LAKE CITY, UT—May 11, 2017—ApolloDx, a medical diagnostic company, today announced that it has been awarded a National Institute of Health (NIH) Phase 1 grant to develop an aptamer-based portable biosensor device to test for acetazolamide (ACZ) in patient urine. Results from this grant will allow pharmaceutical companies to monitor patient compliance in clinical drug trials. Patient noncompliance with clinical trial regimens can affect the ability of the Food and Drug Administration (FDA) to fairly judge a drug candidate and costs the pharmaceutical industry and healthcare in general billions in added expenses due to faulty data.
“We are very pleased NIH expressed strong support for ApolloDx’s track record and expertise in developing this novel test, which is really about patient safety and therapeutic effectiveness,” said Jared Bauer, ApolloDx CEO. “Our technology will allow us to develop a test so pharmaceutical companies can more accurately monitor protocol compliance, receive better data faster and avoid compromised clinical trials resulting in potentially accelerated FDA review, more accurate labeling and ultimately better outcomes for patients,” Jared concluded.
In reviewing ApolloDx’s application, one member of the NIH Grant review committee pointed to the seriousness of the problem of compromised clinical data. “Patient non-adherence during clinical trials can adversely impact the trial data, resulting in a potential negative FDA review and premature termination of a drug development program. This is a significant issue and this (ApolloDx) technology has the capabilities of providing a solution.”
ApolloDx is a Salt Lake City based medical diagnostic company dedicated to developing a state-of-the-art handheld device that provides reliable results to medical professionals within minutes of testing patient samples. ApolloDx technology offers a new testing paradigm utilizing advanced technology and decentralized testing in conjunction with backend connectivity to centralized data repositories. ApolloDx technology is based on using test strips with a proprietary APOLLOMER™ probe to bind to the substance of interest in the test sample. The strips can be developed to detect almost any substance in a liquid sample. The binding allows the handheld analyzer to detect the analyte. The analyzer then performs an electrochemical analysis with an app and reports the test result to a smart device. Test results from all locations can be delivered in real time to end users through the cloud and web interface. For more information please visit our website: http://apollodx.com/
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding ApolloDx’s plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to ApolloDx’s business which could significantly affect expected results, including without limitation progress of product development, ability to raise capital to fund product development, testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and ApolloDx undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Contact: Bill Pagels, CSO, 801-796-2918 ext. 109